Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | The US Chronic Pain Market - Focus on Opioids: (2014-2019) – Daedal ResearchThe report titled “The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)” provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies).
By: Daedal Research Segment Coverage Oxycodone Hydrocodone Morphine Hydromorphone Fentanyl Dihydrocodeine Methadone Company Coverage Zogenix Inc. Egalet Corporation NektarTheropeutics Executive Summary Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating. The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market. Table of Contents: 1. Executive summary 2. Introduction: 3. The US Chronic Pain Therapy Market 3.1 Opioid Sales in US Chronic Pain Market: Sizing & Growth 3.2 Opioid Sales in US Chronic Pain Market - Forecast: Sizing & Growth 4. The US Chronic Pain Therapy Market: Segment Analysis 4.1 The US Oxycodone Market: Size and Growth 4.2 The US Methadone Market: Size and Growth 4.3 The US Morphine Market: Size and Growth 4.4 The US Hydromorphone Market: Size and Growth 4.5 The US Hydrocodone Market: Size and Growth 4.6 The US Dihydrocodeine Market: Size and Growth 4.7 The US Fentanyl Market: Size and Growth 5. The US Chronic Pain Therapy: Market Share Analysis 6. Growth Drivers and Challenges:The US Chronic Pain Therapy Market 6.1 Growth Drivers 6.1.1 Rising Healthcare Expenditures 6.1.2 Rise in Aging Demographics 6.1.3 Economic Development 6.2 Market Challenges 7. The US Chronic Pain Therapy Market Trends 7.1 Increasing number of Drug Approvals 7.2 Incidence of pain conditions in the US households 8. Competitive Landscape:The US Chronic Pain Therapy Market 9. Company Profiles:The US Chronic Pain Therapy Market 9.1 ZogenixInc 9.1.1 Business Overview 9.1.2 Financial Overview 9.1.3 Business Strategies 9.2 Egalet Corporation 9.2.1 Business Overview 9.2.2 Financial overview 9.2.3 Business Strategies 9.3 NektarTheropeutics 9.3.1 Business Overview 9.3.2 Financial overview 9.3.3 Business Strategies List of Figures: Table 1: Types of Acute and Chronic pain Table 2: WHO Guidelines for Pain Therapy Figure 1: US Opioid Sales in Chronic Pain Therapy Market: 2009-2013 (in US$ billions) Figure 2: US Opioid Sales in Chronic Pain Therapy Market - Forecast: 2014F-2019F (US$ B) Figure 3: US Oxycodone Market: by value- 2009-2013 (in US$ billion) Figure 4: Oxycodone Market: Share of Leading Players (2027) Figure 5: US Oxycodone Market: By value – Forecast: 2014F-2019F (in US$ billion) Figure 6: US Methadone Market: by Value- 2009-13 (in US$ million) Figure 7: US Methadone Market: By value – Forecast: 2014F-2019F (in US$ million) Figure 8: US Morphine Market: by value- 2009-13 (in US$ million) Figure 9: US Morphine Market: By value – Forecast: 2014F-2019F (in US$ million) Figure 10: US Long- Acting Morphine Market: 2014 Figure 11: US Hydromorphone Market: by Value- 2009-13 (in US$ million) Figure 12: US Hydromorphone Market: By value – Forecast: 2014F-2019F (in US$ million) Figure 13: US Hydrocodone Market: by Value- 2009-13 (in US$ billion) Figure 14: US Hydrocodone Market: By value – Forecast: 2014F-19F (in US$ billion) Figure 15: US Dihydrocodeine Market: by Value- 2009-13 (in US$ billion) Figure 16: US Dihydrocodeine Market: By value – Forecast: 2014F-19F (in US$ billion) Figure 17: US Fentanyl Market: by value- 2009-13 (in US$ million) Figure 18: US Fentanyl Market: By value – Forecast: - 2014F-19F (in US$ million) Figure 19: The US Chronic Pain Therapy Market: Share of Opioids, 2013 Figure 20: US Healthcare Expenditures per Capita, 2007-2013E (in US$) Figure 21: Growth of the US Aging population, 60 years and above as a percentage of total population, 2007-13E (in%) Figure 22: US GDP, 2007-13E (in Current US$ trillions) Figure 23: Number of Drugs Approval by FDA, 2000-2009 Figure 24: Incidence of Pain in the US (in%) Table 3: Leading Players of US Chronic Pain Therapy Market Table 4: US Chronic Pain Therapy Market: Key Players and their product areas Figure 25: Percentage share of Long Acting Morphine – Value (in %) Table 5: Long Acting Morphine: Competition and Market Share Table 6: US Chronic Pain Therapy Market: Sales of Leading Companies Figure 26: Zogenix Inc. Product Revenue, FY 2011-13 (in US$ million) Figure 27: Zogenix Inc. R&D Expenditure, FY 2011-13 (in US$ million) Table 7: Products offered by Egalet Figure 28: Egalet Revenue, FY 2011-13 (in US$ millions) Figure 29: Egalet R&D Expenditure, FY 2011-12 (in US$ million) Figure 30: Nektar Product Revenue, FY 2011-13 (in US$ million) Figure 31: Nektar R&D Expenditure, FY 2011-13 (in US$ million) For further details, kindly visit : http://www.daedal- Rajeev Kumar (Business Development Manager) Address: 36 SFS Flats Paschim Vihar New Delhi-110063 Mobile: +91-8743975789 Tel: +91-120-4553017 Mail ID - info@daedal- Daedal Research is a research and consulting firm specialized in providing research reports and customized business research and analysis. For more Information: http://www.daedal- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|